Duke Comp Cancer Ctr Core Support Grant

杜克综合癌症中心（DCCC）负责并授权作为所有杜克的中心 我们的目标是为癌症患者提供服务，并将这些活动的好处带给我们的社区和社会。作为矩阵中心 由国家癌症研究所（NCI）持续支持超过31年，DCCC利用杜克的 基础研究基础设施与卓越的临床肿瘤学研究，这是通过治疗4,800个新的 癌症患者，每年招募1,000多名患者进行治疗性临床试验，并通过以下措施增强 国家肿瘤学研究资源的存在，如两个国家癌症研究所资助的数据和统计中心 合作团体。这些癌症研究活动得到了NCI 4800万美元资金的支持（增加了2700万美元 从1998年起）和近1.71亿美元的总研究经费（从1998年起增加了6600万美元），并由 DCCC和其他40个中心、SPORE和计划项目赠款以及合作协议。在这 竞争性续期申请，我们要求支持358名成员（自1998年以来增加了68名）， 11个研究项目由17个共享资源支持。在基础科学方面取得了重大进展， DCCC研究人员包括：DNA错配修复机制的理解，Ras结构的作用 MD信号传导和产生靶向激素受体的新型抗癌剂。这些新技术正在 与临床和人群研究相平衡，例如第一次临床试验证明了新类别的益处 抗癌化合物、抗血管生成剂和α发射体211-Astatine的开发和应用 脐带血干细胞移植是一种重要的造血干细胞移植方法。 以及使用基因表达阵列分析来预测乳腺癌临床结果的示范。的 DCCC受益于一项为期五年的筹款活动，该活动产生了1.13亿美元的慈善捐款。 支持，产生了新的实验室和行政空间，使新的发展计划， 器官发生/干细胞生物学和成像，并能够增强共享资源，如 生物信息学，组织和血液采购，临床细胞处理。本申请支持 美国国防部协调委员会阐明了推动国防部协调委员会充分利用巨大的 生物医学研究的进展，以改善和延长癌症患者的生命，并有风险， 癌症，并将这些应用于社会。

The Duke Comprehensive Cancer Center (DCCC) is charged and empowered to serve as the center of all Duke activities in cancer and to deliver the benefits of these activities to our community and society. As a matrix center continuously supported by the National Cancer Institute (NCI) for over 31 years, the DCCC leverages Duke's basic research infrastructure with clinical oncology research excellence which is enabled by treating 4,800 new cancer patients annually, enrolling over 1,000 patients annually onto therapeutic clinical trials, and is enhanced by the presence of national oncology research resources, such as the data and statistical centers of two NCI-funded cooperative groups. These cancer research activities are supported by $48M in NCI funding (a $27M increase from 1998) and nearly $171M in total research funding (a $66M increase from 1998) and are coordinated by the DCCC and forty other center, SPORE and program project grants as well as cooperative agreements. In this competitive renewal application, we request support for 358 members (an increase of 68 since 1998) working in 11 Research Programs supported by 17 Shared Resources. Significant basic scientific advances have been made by DCCC investigators including: an understanding of DNA mismatch repair mechanisms, the role of Ras structure md signaling, and the generation of novel anti-cancer agents targeting hormone receptors. These advances are balanced with clinical and population studies such as the first clinical trial demonstrating a benefit of a new class of anti-cancer compounds, the anti-angiogenesis agents and the alpha emitter 211-Astatine; the development and demonstration of the use of umbilical cord blood as a source of stem cells for transplantation; and the development and demonstration of the use of gene expression array profiling to predict clinical outcomes in breast cancer. The DCCC has benefited from a five-year fund raising campaign which generated $113 million in philanthropic support, generated new laboratory and administrative space, enabled new Programs-in-Development in Organogenesis/Stem Cell Biology and Imaging, and enabled enhancement of Shared Resources such as Bioinformatics, Tissue and Blood Procurement, and Clinical Cellular Processing. This application for support of the DCCC articulates the principles, goals and strategies for propelling the DCCC to fully leverage the enormous advances in biomedical research to improve and extend the lives of cancer patients with cancer and at risk for cancer, and delivering these to society.